KOMBOGLYZE(TM) Receives Marketing Authorisation in the European Union for Adult Patients With Type 2 Diabetes

Paris and London, November 29 (ots/PRNewswire) -

Bristol-Myers Squibb Company and AstraZeneca announced today
that the European Commission has granted marketing authorisation for
KOMBOGLYZETM (saxagliptin and metformin HCl immediate-release fixed
dose combination) that will cover the 27 Member States of the
European Union.

The indication for KOMBOGLYZE is as an adjunct to diet and
exercise to improve glycaemic control in adult patients aged 18 years
and older with Type 2 diabetes mellitus inadequately controlled on
their maximally tolerated dose of metformin alone or those already
being treated with the combination of saxagliptin and metformin as
separate tablets.

KOMBOGLYZE combines saxagliptin (ONGLYZA(R))*, a DPP-4 inhibitor,
and metformin immediate-release (metformin IR), a biguanide, in one
convenient tablet for the treatment of Type 2 diabetes. The approval
of KOMBOGLYZE is based on a saxagliptin development programme that
involved 4,326 patients, including 2,158 individuals receiving
saxagliptin plus metformin. In the development programme, saxagliptin
and metformin were administered as separate components. The
bioequivalence of KOMBOGLYZE to co-administered saxagliptin and
metformin was demonstrated in additional studies.

* Onglyza received Marketing Authorisation in 2009 and is
indicated in adult patients aged 18 years and older with type 2
diabetes mellitus to improve glycaemic control: in combination with
metformin, when metformin alone, with diet and exercise, does not
provide adequate glycaemic control; in combination with a
sulphonylurea, when the sulphonylurea alone, with diet and exercise,
does not provide adequate glycaemic control in patients for whom use
of metformin is considered inappropriate; in combination with a
thiazolidinedione , when the thiazolidinedione alone with diet and
exercise, does not provide adequate glycaemic control in patients for
whom use of a thiazolidinedione is considered appropriate.[1]

About Type 2 Diabetes

By the end of 2011, diabetes is estimated to affect nearly 53
million people aged 20-79 in Europe, and this figure is projected to
rise to more than 64 million by 2030.[2] Type 2 diabetes accounts for
approximately 90 to 95% of all cases of diagnosed diabetes in adults.
Type 2 diabetes is a chronic, progressive disease characterised by
insulin resistance and/or dysfunction of beta cells in the pancreas,
which decreases insulin sensitivity and secretion, leading to
elevated blood glucose levels. Over time, this sustained
hyperglycaemia contributes to worsening insulin resistance and
further beta cell dysfunction. Significant unmet needs exist as
nearly half of treated patients remain uncontrolled on their current
glucose-lowering regimen.

Bristol-Myers Squibb and AstraZeneca Collaboration

Bristol-Myers Squibb and AstraZeneca entered into a collaboration
in January 2007 to enable the companies to research, develop and
commercialise select investigational drugs for Type 2 diabetes. The
Bristol-Myers Squibb/AstraZeneca diabetes collaboration is dedicated
to global patient care, improving patient outcomes and creating a new
vision for the treatment of Type 2 diabetes.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical
business with a primary focus on the discovery, development and
commercialisation of prescription medicines for gastrointestinal,
cardiovascular, neuroscience, respiratory and inflammation, oncology
and infectious disease. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding product development. Such forward-looking statements
are based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Among other risks, there can be no guarantee that
Komboglyze will become a commercially successful product.
Forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Bristol-Myers
Squibb's business, particularly those identified in the cautionary
factors discussion in Bristol-Myers Squibb's Annual Report on Form
10-K for the year ended December 31, 2010, in our Quarterly Reports
on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers
Squibb undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.

AstraZeneca Forward-Looking Statement

The statements contained herein include forward-looking
statements. Although we believe our expectations are based on
reasonable assumptions, any forward-looking statements, by their very
nature, involve risks and uncertainties and may be influenced by
factors that could cause actual outcomes and results to be materially
different from those predicted. The forward-looking statements
reflect knowledge and information available at the date of the
preparation of this press release and the Company undertakes no
obligation to update these forward-looking statements. Important
factors that could cause actual results to differ materially from
those contained in forward-looking statements, certain of which are
beyond our control, include, among other things, those risk factors
identified in the Company's Annual Report and Form 20-F Information
2010. Nothing contained herein should be construed as a profit
forecast.

References

1. Onglyza Summary of Product Characteristics. October 2011

2. International Diabetes Federation (IDF). IDF Diabetes Atlas.
5th Edition. November 2011. http://www.idf.org/diabetesatlas [Last
accessed: 14 November 2011]

ots Originaltext: Bristol-Myers Squibb & AstraZeneca
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media: Carmel Hogan, Bristol-Myers Squibb, +33-6-74-10-76-58,
carmel.hogan@bms.com; Michele Meixell, AstraZeneca, +1-610-662-3589,
michele.meixell@astrazeneca.com;
Investors: John Elicker, Bristol-Myers Squibb, +1-609-252-4611,
john.elicker@bms.com; Karl Hard, AstraZeneca, +44-20-7604-8123,
karl.j.hard@astrazeneca.com